Long Road For Daiichi Sankyo’s Quizartinib Gets Longer As FDA Extends Review Time

 
• By Alaric DeArment
The FDA extended the PDUFA date for Daiichi Sankyo's quizartinib by three months • Source: Shutterstock

More from Anticancer

More from Therapeutic Category